This displayed a dramatic improvement in the management of PTLD patients as anti-EBV CTLs of different HLA specificities may be generated and banked in advance in order to be readily available when needed. providers are now available to stimulate immune effector functions or counteract immunosuppressive mechanisms, such as manufactured antitumor T cells, co-stimulatory receptor agonist, … Continue reading This displayed a dramatic improvement in the management of PTLD patients as anti-EBV CTLs of different HLA specificities may be generated and banked in advance in order to be readily available when needed